Fantastic work by Reuben Ben-David. A lot more work to do, but this is possibly the biomarker we have been looking for to help risk stratify clinically localized #bladdercancer patients to more appropriate therapies. Sia Daneshmand, M.D. Ashish M. Kamat, MD, MBBS Bernie Bochner, MD Peter Black

Register now for this upcoming CME course on cutting edge treatments in GU oncology 🦀. nam02.safelinks.protection.outlook.com/?url=https%3A%… Featuring amazing faculty Chris Anderson james mckiernan Ojas Shah Izak Faiena #joeldecastro Katie Spina (she/her) Mark Stein Dr. John Sfakianos Chris Barbieri … and more!

Cutaneous ureterostomies have been a game changer for a lot of our patients… easy to leave stents in and change in the office. Mount Sinai Department of Urology

What a pleasure to work and publish with these giants in the field Matt Galsky and Dr. John Sfakianos. Novel bladder-sparing approaches for optimal candidates with MIBC are an important alternative for radical cystectomy. Tumor-informed ctDNA and mpMRI with VI-RADS score may

This Bladder Cancer Awareness Month, we express gratitude to the #WorldGU24 #BladderCancer faculty! Drs. Shilpa Gupta, Sia Daneshmand, M.D., Matt Galsky, Andrea Apolo, M.D., Ashish M. Kamat, MD, MBBS, Matt Milowsky, Sima Porten, Dr. John Sfakianos,Jonathan Rosenberg MD,Guru P. Sonpavde, MD, Sandy Srinivas hubs.la/Q02vB8Pc0

Thxful for opp to have our PH1/2 IIT data with 2141-V11 anti CD40 therapy for bcg unresp NMIBC presented at Amer. Urol. Assn. 2024. Amazing team Memorial Sloan Kettering Cancer Center Rockefeller University Jeff Ravetch ⭐️fellow Muneeb Alam Juan C Osorio MD Jonathan Rosenberg MD Eugene Pietzak UrologyMSK Society of Urologic Oncology

Bladder cancer TME-specific TGF-β & hypoxia directly suppress NK cell function via O2-dependent reduction in SLAMF6 signaling Adam Farkas Bhardwaj Lab Michelle Alyssa Tran, PhD Michelle Alyssa Tran, PhD Dr. John Sfakianos Horowitz Lab @Icahn School of Medicine Mount Sinai biorxiv.org/content/10.110…

Had an excellent video abstract session at AUA 24 describing the difficult intracorporeal neobladder and techniques to bring the ileum down. A huge shout-out to my mentors Peter Wiklund Reza Mehrazin, MD Dr. John Sfakianos for innovating these brilliant strategies! #AUA24

Amazing job Neeraja Tillu. Many tricks have been developed over the years very very rare we can’t bring down an intracorporeal neobladder. Mount Sinai Department of Urology The Tisch Cancer Institute

Inaugural Mount Sinai Kidney Stone Symposium was a huge success! Be mindful of laser settings, temperature and pressure!#AUA2024 Thanks Ash Tewari, MD Mantu Gupta, M.D. Mount Sinai Department of Urology and to our panelists Khurshid Ghani Dr. Ben Chew Johnathan A. Khusid, MD Esteban Emiliani

Fantastic work by Michelle Alyssa Tran, PhD and team… great resource manuscript uncovering a plethora of immune knowledge found in the urine of patients with bladder cancer. Mount Sinai Department of Urology The Tisch Cancer Institute

En garde! It's a fencing duel at the #WorldGU24 Debate Championships! 🤺 Dr. Jason Efstathiou vs Dr. John Sfakianos will clash over Chemo-RT vs Radical Cystectomy in the Treatment of MIBC. Who will land the decisive hit? Comment below! hubs.la/Q02GcxNf0

Great discussion by Ketan K. Badani MD at the 2nd annual Chilean Course on kidney and testicular cancer. Mount Sinai Department of Urology The Tisch Cancer Institute

Thank you very much for the invitation and above and beyond hospitality. Truly an amazing experience. Mount Sinai Department of Urology

Using #scRNAseq in a study funded by our division, Michelle Alyssa Tran, PhD, Adam Farkas, Matt Galsky, Dr. John Sfakianos, Bhardwaj Lab, et al. revealed insights into the #BladderCancer immune microenvironment JExpMed rupress.org/jem/article-ab….

ctDNA is preparing for its prime time in the management of MIBC. Dive with us beyond the abstract, in this featured article in UroToday.com Dr. John Sfakianos urotoday.com/recent-abstrac… via UroToday.com

Exciting times for improving treatment decision making for patients with #bladdercancer. The Tisch Cancer Institute Mount Sinai Department of Urology Natera

In our analysis of over 400 RARCs, positive lymph node disease was linked to poor prognosis (a known finding). However, a subset of patients with undetectable ctDNA status showed a favorable prognosis, regardless of lymph node involvement. Can we avoid adjuvant therapy in these

Undetectable ctDNA Before RC Predicts 🔼 Outcomes UroToday.com #IBCN2024 Dr. John Sfakianos IBCN 🇨🇭n=134 🇨🇭n=85 (63.4%) pts had MIBC, 25 (29.4%) had NAC - Med F/U 10 mos: 40 (29.9%) pts had dx relapse 🇨🇭Undetect vs Detect ctDNA, 12 mo RFS rate: 93% vs 40% 🇨🇭Undetect ctDNA: 🔼

Undetectable ctDNA status before radical cystectomy predicts improved outcomes. Presentation by Dr. John Sfakianos Icahn School of Medicine at Mount Sinai. #IBCN2024 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4gz149K IBCN